业界动态国内医卫资讯

口服IL-23拮抗剂Icotrokinra改善PsA症状

Medscape News · 2026-11-12 14:47

摘要

这项3期试验发现关节反应、身体功能和皮肤清除均有改善,16周时未出现新的安全性信号。Medscape Medical News

English
Oral IL-23 Antagonist Icotrokinra Improves PsA Symptoms

The phase 3 trial finds improvements in joint response, physical function, and skin clearance, with no new safety signals at 16 weeks. Medscape Medical News

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界